General Information of Drug (ID: DMDFC2Y)

Drug Name
VIC-1911 Drug Info
Synonyms TAS 119
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDFC2Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Aurora kinase A (AURKA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
MLN8237 DMO8PT9 Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [4]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [6]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [4]
LY3295668 DM8RJTB Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
MLN8054 DMUANF3 Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of VITRAC Therapeutics.
2 A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
3 Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
4 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
6 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
7 Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
9 Clinical pipeline report, company report or official report of Cyclacel.